Viridaxis is a biotechnology firm working for integrated pest management.

Viridaxis is a biotechnology firm working for integrated pest management.

Company (Alive / Active)

All investors data 2 Investors
  • Société Régionale d'Investissement de Wallonie
  • Vives



97 Chaussee de Charleroi


Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Viridaxis $1.3M Oct 15, 2007
See all 15 competitors

Web Traffic


Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Page Views Per Million (PVPM)
Reach Per Million

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Viridaxis Jobs

jobs by Indeed job


Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.


Company Status Description Investors

Calibrant Biosystems

Gaithersburg, Maryland, United States
Dead / InactiveCalibrant Biosystems specializes in the discovery and validation of protein biomarkers. Calibrant's proprietary biomarker discovery platform enables quantitative protein profiling of human tissue samples. With sample requirements uniquely matched to microdissection methods including laser capture microdissection (LCM), and coupled with an integrated bioinformatics suite enabling effective data mining from combined genomic and proteomic data, Calibrant's approach to biomarker discovery provides u...Show allLogin to see details


Siena, Italy
Alive / ActivePhilogen is a clinical-stage biotechnology company engaged in the discovery and development of biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications.Login to see details
See all 15 competitors


Title Application Date Patent Date Status
(Patent / Application)